C-SLAM

C-SLAM study: LDV/SOF vs SOF + SMV in acute hepatitis C

Basu PP. AASLD 2015, Abs. 1074

Anti-HCV
Simeprevir
Ledipasvir
Sofosbuvir
Genotype
1
Special population
Acute HCV infection

DOWNLOAD THIS SLIDE KIT

BROWSE SLIDES

Design

Objective

  • SVR12 (undetectable HCV RNA)

Baseline characteristics and outcome

Adverse events

Summary

  • High SVR12 with short course of 2 HCV drugs in acute HCV infection
    • Overall rate of 100% by per protocol, 93% by ITT analysis
  • Minimal adverse events
  • Studies with larger number of patients needed